Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by Taichung Veterans General Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Tri-Service General Hospital
Information provided by:
Taichung Veterans General Hospital
ClinicalTrials.gov Identifier:
NCT00417950
First received: January 1, 2007
Last updated: January 3, 2007
Last verified: January 2007
  Purpose

To understand if acarbose, an alpha-glucosidase inhibitor usually for treating diabetes, will further lower post meal glucose and inflammatory state when taking together with moderate amount of alcohol during meal tolerance test in subjects with impaired glucose tolerance or mild diabetes.


Condition Intervention
Diabetes Mellitus
Impaired Glucose Tolerance
Drug: Acarbose

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Taichung Veterans General Hospital:

Primary Outcome Measures:
  • Postprandial hyperglycemia

Secondary Outcome Measures:
  • Postprandial inflammatory responses
  • Postprandial oxidative stress

Estimated Enrollment: 30
Study Start Date: January 2007
  Eligibility

Ages Eligible for Study:   25 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with mild diabetes without prior medications or impaired glucose tolerance

Exclusion Criteria:

  • Pregnancy
  • Recent major cardiac, renal and hepatic disease
  • Intolerance to alcohol
  • Allergy to acarbose treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00417950

Contacts
Contact: I Te Lee, MD, MS 886-4-23592525 ext 3065 itlee@vghtc.gov.tw

Locations
Taiwan
Taichung Veterans General Hospital Recruiting
Taichung, Taiwan
Contact: Wayne H Sheu, MD, PhD    886-4-23592525 ext 3068    whhsheu@vghtc.gov.tw   
Principal Investigator: Wayne H Sheu, MD, PhD         
Sub-Investigator: I Te Lee, MD, MS         
Sponsors and Collaborators
Taichung Veterans General Hospital
Tri-Service General Hospital
Investigators
Principal Investigator: Wayne H Sheu, MD, PhD Taichung Veterans General Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00417950     History of Changes
Other Study ID Numbers: 950801/C06138
Study First Received: January 1, 2007
Last Updated: January 3, 2007
Health Authority: Taiwan: Department of Health

Keywords provided by Taichung Veterans General Hospital:
diabetes
acarbose
alcohol
inflammation
oxidative stress
Mild diabetes mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperglycemia
Acarbose
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 19, 2014